Art. -Nr.: HY-18975

I-BRD9

Name: I-BRD9
Brand: MedChemExpress
SKU: HY-18975
Price: 99.00 USD
Availability: InStock
Rating: 5 (10 reviews)

10 Cited Publications

Kundenbewertung

Based on 10 publication(s) in Google Scholar

I-BRD9 is a selective cellular chemical probe of bromodomain-containing protein 9 (BRD9) with pIC₅₀ value of 7.3 μM. I-BRD9 has high selectivity for bromodomain and extra terminal domain (BET) family and highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 can be used to identify genes regulated by BRD9 in Kasumi-1 cells involved in oncology and immune response pathways.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.72%
CAS. Nr.: 1714146-59-4
Formel: C₂₂H₂₂F₃N₃O₃S₂
Molecular Weight:497.55

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

I-BRD9 Chemical Structure

CAS. Nr.: 1714146-59-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (10)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
G-401	IC₅₀	0.008 μM Compound: Chemical probe: I-BRD9	Anti-proliferative activity against human G-401 cells assessed as inhibition cell growth incubated for 72 hrs in presence of vincristine by MTT-based Chou-Talalay method Anti-proliferative activity against human G-401 cells assessed as inhibition cell growth incubated for 72 hrs in presence of vincristine by MTT-based Chou-Talalay method	[PMID: 28714904]
G-401	IC₅₀	0.096 μM Compound: Chemical probe: I-BRD9	Anti-proliferative activity against human G-401 cells assessed as inhibition cell growth incubated for 72 hrs in presence of doxorubicin by MTT-based Chou-Talalay method Anti-proliferative activity against human G-401 cells assessed as inhibition cell growth incubated for 72 hrs in presence of doxorubicin by MTT-based Chou-Talalay method	[PMID: 28714904]
G-401	IC₅₀	13.4 μM Compound: Chemical probe: I-BRD9	Anti-proliferative activity against human G-401 cells assessed as cell viability incubated for 72 hrs by MTT assay Anti-proliferative activity against human G-401 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 28714904]
G-401	IC₅₀	6.1 μM Compound: Chemical probe: I-BRD9	Anti-proliferative activity against human G-401 cells assessed as cell viability incubated for 144 hrs by MTT assay Anti-proliferative activity against human G-401 cells assessed as cell viability incubated for 144 hrs by MTT assay	[PMID: 28714904]
G-401	IC₅₀	9.1 μM Compound: Chemical probe: I-BRD9	Anti-proliferative activity against human G-401 cells assessed as inhibition cell growth incubated for 72 hrs in presence of carboplatin by MTT-based Chou-Talalay method Anti-proliferative activity against human G-401 cells assessed as inhibition cell growth incubated for 72 hrs in presence of carboplatin by MTT-based Chou-Talalay method	[PMID: 28714904]
HL-60	GI₅₀	0.433 μM Compound: Chemical probe: I-BRD9	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth for 7 days by cell titre glo assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth for 7 days by cell titre glo assay	[PMID: 27376689]
Jurkat	GI₅₀	3.643 μM Compound: Chemical probe: I-BRD9	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth for 7 days by cell titre glo assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth for 7 days by cell titre glo assay	[PMID: 27376689]

In Vitro

I-BRD9 (10 μM, 6 h) has a regulation role in cancer and immunology pathways^[1].
I-BRD9 (10 μM) has high BRD9 affinity and excellent broader bromodomain selectivity^[1].
I-BRD9 (10 μM) has affinity for BRD9 (TR-FRET), BRD4 BD1 (TR-FRET) and BRD9 NanoBRET with pIC₅₀ values of 7.3 μM, 5.3 μM and 6.8 μM^[1].
I-BRD9 (10 μM) has high aqueous solubility (CLND) with 359 μM^[1].
I-BRD9 (10 μM) displays >625 fold selectivity in binding with endogenous BRD9 against BET family member BRD3 in HUT-78 cell lysate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

Kasumi-1 cells
Concentration:

10 μM
Incubation Time:

6 h
Result:

Showed 4 genes (CLEC1, 62 DUSP6, 63 FES64 and SAMSN165) that were strongly down-regulated and not by I-BET151.

Chemical Information

CAS. Nr. 1714146-59-4
Appearance Solid
Molecular Weight 497.55
Formel C₂₂H₂₂F₃N₃O₃S₂
Color White to off-white
SMILES

N=C(C(S1)=CC2=C1C(C3=CC=CC(C(F)(F)F)=C3)=CN(CC)C2=O)NC(CC4)CCS4(=O)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All WBRT-PCRCell Proliferation/Viability AssayIn Vivo Efficacy StudyCell Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors. [Abstract]

2023 Dec 1;14(1):7762. PMID: 38040699
Sci Adv

BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling. [Abstract]

2025 Apr 25;11(17):eads6385. PMID: 40279411

I-BRD9 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 25;11(17):eads6385. [Abstract]

IB analysis of WCL derived for MDA-MB-231 cells treated with 5 μM I-BRD9 for the indicated time.

I-BRD9 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 25;11(17):eads6385. [Abstract]

RT-qPCR analysis of mRNA levels of select genes commonly regulated by I-BRD9 and ipatasertib. MDA-MB-231 cells were treated with 5 μM I-BRD9 or 1 μM ipatasertib for 16 hours.

I-BRD9 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 25;11(17):eads6385. [Abstract]

MDA-MB-231 cells treated with I-BRD9 (5 μM) or GSK126 were subjected to cell proliferation assays.

I-BRD9 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 25;11(17):eads6385. [Abstract]

Tumor growth curve upon treatment of I-BRD9 (30 mg/kg) and GSK126.

I-BRD9 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 25;11(17):eads6385. [Abstract]

MDA-MB-231 cells treated with I-BRD9 (5 μM) or GSK126 were subjected to colony formation assays.
Proc Natl Acad Sci U S A

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. [Abstract]

2019 Feb 19;116(8):2961-2966. PMID: 30718431
Gene Ther

BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target. [Abstract]

2024 Nov;31(11-12):594-606. PMID: 39306629
Drug Metab Dispos

Switch/sucrose non-fermentable complex interacts with constitutive androstane receptor to regulate drug-metabolizing enzymes and transporters in the liver. [Abstract]

2025 Apr;53(4):100057. PMID: 40158296
Mol Carcinog

PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia. [Abstract]

2023 Aug;62(8):1119-1135. PMID: 37144835
bioRxiv

2026 May 7.
bioRxiv

2025 Sep 7.
bioRxiv

2023 Apr 3.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 13.89 mg/mL (27.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0098 mL

10.0492 mL

20.0985 mL

5 mM

0.4020 mL

2.0098 mL

4.0197 mL

10 mM

0.2010 mL

1.0049 mL

2.0098 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.39 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1.39 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.9 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.39 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1.39 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.9 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.39 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1.39 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (13.9 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Natalie H Theodoulou, et al. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. J Med Chem [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0098 mL	10.0492 mL	20.0985 mL	50.2462 mL
	5 mM	0.4020 mL	2.0098 mL	4.0197 mL	10.0492 mL
	10 mM	0.2010 mL	1.0049 mL	2.0098 mL	5.0246 mL
	15 mM	0.1340 mL	0.6699 mL	1.3399 mL	3.3497 mL
	20 mM	0.1005 mL	0.5025 mL	1.0049 mL	2.5123 mL
	25 mM	0.0804 mL	0.4020 mL	0.8039 mL	2.0098 mL

Bioz

Keywords

I-BRD9

10 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

I-BRD9

Publications Citing Use of MedChemExpress (MCE) I-BRD9

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen